Across state lines: Fulminant Babesia microti infection in a liver transplant recipient

Transplant Infectious Disease

Volumn 19, Issue 5, 2017, Pages

  Meissner, Eric G ^a,b   McGillicuddy, John W ^b   Squires, Jerry ^b   Skipper, Daniel ^b   Self, Sally ^b   Wray, Dannah ^a   Moritz, Erin D ^c   Stramer, Susan L ^c   Nadig, Satish ^b  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^c AMERICAN RED CROSS   (United States)

Author keywords

Babesia microti; blood transfusion; liver transplantation

Indexed keywords

ATOVAQUONE; AZITHROMYCIN; CLINDAMYCIN; DOXYCYCLINE; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; LEDIPASVIR PLUS SOFOSBUVIR; MYCOPHENOLATE MOFETIL; PREDNISONE; QUINIDINE GLUCONATE; TACROLIMUS; ANTIINFECTIVE AGENT; ANTIMALARIAL AGENT; QUINIDINE;

ADULT; ARTICLE; BABESIA MICROTI; BLOOD SAMPLING; BLOOD SMEAR; BLOOD TRANSFUSION; CASE REPORT; CLINICAL ARTICLE; DECOMPENSATED LIVER CIRRHOSIS; GRAFT RECIPIENT; HEPATITIS C; HUMAN; HUMAN TISSUE; IMMUNOFLUORESCENCE; IMMUNOSUPPRESSIVE TREATMENT; LIVER BIOPSY; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; MINNESOTA; NONHUMAN; PARASITE TRANSMISSION; PARASITEMIA; PIROPLASMOSIS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; TREATMENT DURATION; ANALOGS AND DERIVATIVES; BABESIA; BLOOD; BLOOD DONOR; EXCHANGE BLOOD TRANSFUSION; ISOLATION AND PURIFICATION; MICROBIOLOGY;

ANTI-BACTERIAL AGENTS; ANTIMALARIALS; BABESIA; BABESIOSIS; BLOOD DONORS; BLOOD TRANSFUSION; CLINDAMYCIN; EXCHANGE TRANSFUSION, WHOLE BLOOD; HUMANS; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; QUINIDINE;

EID: 85026433735     PISSN: 13982273     EISSN: 13993062     Source Type: Journal    
DOI: 10.1111/tid.12741     Document Type: Article

References (11)

1. Herwaldt BL, Linden JV, Bosserman E, Young C, Olkowska D, Wilson M. Transfusion-associated babesiosis in the United States: A description of cases. Ann Intern Med. 2011;155:509-519.
2. Brennan MB, Herwaldt BL, Kazmierczak JJ, et al. Transmission of Babesia microti parasites by solid organ transplantation. Emerg Infect Dis. 2016;22:1869-1876.
3. Leiby DA, Johnson ST, Won KY, et al. A longitudinal study of Babesia microti infection in seropositive blood donors. Transfusion. 2014;54:2217-2225.
4. Moritz ED, Winton CS, Tonnetti L, et al. Screening for Babesia microti in the U.S. blood supply. N Engl J Med. 2016;375:2236-2245.
5. Adams D, Fullerton K, Jajosky R, et al. Summary of notifiable infectious diseases and conditions—United States, 2013. MMWR Morb Mortal Wkly Rep. 2015;62:1-122.
6. Food and Drug Administration. Fatalities reported to FDA following blood collection and transfusion: Annual summary for fiscal year 2014. Silver Spring, MD: Food and Drug Administration; 2016. http://www.fda.gov/downloads/BiologicsBloodVaccines/SafetyAvailability/ReportaProblem/TransfusionDonationFatalities/UCM459461.pdf. Accessed February 2017.
7. Food and Drug Administration. Meeting of the Blood Products Advisory Committee. Strategies for implementation of antibody and nucleic acid-based testing for Babesia microti in blood donors, May 13, 2015. http://www.fda.gov/AdvisoryCommittees/CommitteesMeetingMaterials/BloodVaccinesandOtherBiologics/BloodProductsAdvisoryCommittee/ucm441228.htm. Accessed February 2017.
8. Vannier E, Krause PJ. Human babesiosis. N Engl J Med. 2012;366:2397-2407.
9. Krause PJ, Gewurz BE, Hill D, et al. Persistent and relapsing babesiosis in immunocompromised patients. Clin Infect Dis. 2008;46:370-376.
10. Slovut DP, Benedetti E, Matas AJ. Babesiosis and hemophagocytic syndrome in an asplenic renal transplant recipient. Transplantation. 1996;62:537-539.
11. Lux JZ, Weiss D, Linden JV, et al. Transfusion-associated babesiosis after heart transplant. Emerg Infect Dis. 2003;9:116-119.